Are Analysts Bullish Bio-Techne Corporation (NASDAQ:TECH) After Last Week?

May 24, 2018 - By Henry Gaston

Bio-Techne Corporation (NASDAQ:TECH) LogoInvestors sentiment decreased to 0.98 in 2017 Q4. Its down 0.23, from 1.21 in 2017Q3. It turned negative, as 27 investors sold Bio-Techne Corporation shares while 88 reduced holdings. 34 funds opened positions while 79 raised stakes. 35.53 million shares or 1.06% less from 35.91 million shares in 2017Q3 were reported.
Fifth Third National Bank & Trust reported 0% stake. Spark Invest Mngmt Ltd Liability Corporation has 0.03% invested in Bio-Techne Corporation (NASDAQ:TECH) for 4,500 shares. Stone Run Cap Limited Liability Co reported 2.66% stake. Bamco owns 1.52M shares. Cornerstone Advsr Inc invested 0% in Bio-Techne Corporation (NASDAQ:TECH). Quantum Mgmt has invested 1.65% in Bio-Techne Corporation (NASDAQ:TECH). 70,000 were reported by State Of Tennessee Treasury Department. Parametric Assoc Llc holds 0.01% or 82,902 shares. Jackson Square Ptnrs Lc holds 931,400 shares or 0.61% of its portfolio. Columbia Wanger Asset Mngmt Llc invested in 0.51% or 264,889 shares. Atlanta Cap Management L L C has invested 1.32% in Bio-Techne Corporation (NASDAQ:TECH). Teachers Retirement Sys Of The State Of Kentucky invested in 0.01% or 7,260 shares. 1,919 were accumulated by Huntington Bank & Trust. Rowland Com Counsel Adv has 19,970 shares for 1.02% of their portfolio. Regions Fincl owns 0% invested in Bio-Techne Corporation (NASDAQ:TECH) for 301 shares.

Since February 13, 2018, it had 0 insider purchases, and 2 insider sales for $845,235 activity. The insider Eansor Norman David sold $164,932.

Bio-Techne Corporation (NASDAQ:TECH) Ratings Coverage

Among 5 analysts covering Bio-Techne Corporation (NASDAQ:TECH), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Bio-Techne Corporation had 8 analyst reports since December 5, 2017 according to SRatingsIntel. The rating was maintained by Robert W. Baird with “Buy” on Thursday, January 18. The stock of Bio-Techne Corporation (NASDAQ:TECH) earned “Buy” rating by Leerink Swann on Thursday, May 3. The stock of Bio-Techne Corporation (NASDAQ:TECH) earned “Buy” rating by Deutsche Bank on Thursday, May 3. The stock of Bio-Techne Corporation (NASDAQ:TECH) has “Buy” rating given on Thursday, March 1 by Deutsche Bank. The company was maintained on Tuesday, February 6 by Robert W. Baird. Craig Hallum maintained it with “Buy” rating and $160.0 target in Wednesday, February 7 report. Stephens maintained it with “Hold” rating and $142.0 target in Wednesday, February 7 report. The stock has “Buy” rating by Leerink Swann on Tuesday, December 5. Below is a list of Bio-Techne Corporation (NASDAQ:TECH) latest ratings and price target changes.

03/05/2018 Broker: Leerink Swann Rating: Buy New Target: $160.0000 Maintain
03/05/2018 Broker: Deutsche Bank Old Rating: Buy New Rating: Buy Old Target: $167 New Target: $165 Maintain
01/03/2018 Broker: Deutsche Bank Old Rating: Buy New Rating: Buy Old Target: $154 New Target: $163 Maintain
07/02/2018 Broker: Stephens Rating: Hold New Target: $142.0 Maintain
07/02/2018 Broker: Craig Hallum Rating: Buy New Target: $160.0 Maintain
06/02/2018 Broker: Robert W. Baird Rating: Buy New Target: $157.0 Maintain
18/01/2018 Broker: Robert W. Baird Rating: Buy New Target: $154.0 Maintain
05/12/2017 Broker: Leerink Swann Rating: Buy Maintain

The stock decreased 0.82% or $1.25 during the last trading session, reaching $151.38. About 112,568 shares traded. Bio-Techne Corporation (NASDAQ:TECH) has risen 45.31% since May 24, 2017 and is uptrending. It has outperformed by 33.76% the S&P500.

Bio-Techne Corporation, together with its subsidiaries, develops, makes, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. The company has market cap of $5.69 billion. It operates through three divisions: Biotechnology, Protein Platforms, and Diagnostics. It has a 51.14 P/E ratio. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets.

More notable recent Bio-Techne Corporation (NASDAQ:TECH) news were published by: Forbes.com which released: “New High For Apple But These 5 Other Nasdaq Favorites Failed To Get There” on May 05, 2018, also Investingnews.com with their article: “Westell Reports Fiscal 2018 Year-End and Fourth Quarter Results” published on May 24, 2018, Investingnews.com published: “Windstream to launch 300 Mbps broadband in North Georgia” on May 24, 2018. More interesting news about Bio-Techne Corporation (NASDAQ:TECH) were released by: Investingnews.com and their article: “5 Top Weekly NASDAQ Tech Stocks: Index Dips Again” published on May 13, 2018 as well as Investingnews.com‘s news article titled: “Harvest Rebalances Blockchain ETF” with publication date: May 23, 2018.

Bio-Techne Corporation (NASDAQ:TECH) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: